该案件可追溯至2022年。时年8月，深交所对未名医药下发关注函称，收到投资者投诉，称杭州强新以 约29亿元入资山东未名全资子公司厦门未名，获得厦门未名约34%的股份，该事项已于2022年5月18日 完成工商变更，根据协议，杭州强新将向厦门未名委派一名董事，要求公司就投资者投诉事项进行核 实。未名医药回复称未查询到相关记录。查阅工商备案材料后，未名医药发现，杭州强新取得厦门未名 34%股权的具体方式为新增其注册资本金，杭州强新以现金方式认缴新增注册资本6767.49万元。 2026.01.02 本文字数：2341，阅读时长大约4分钟 作者 |第一财经 蔡真 第一财经获悉，淄博市中级人民法院日前对未名医药（ST未名，002581.SZ）股权纠纷案作出二审判 决。 根据判决书，被告人潘爱华犯挪用资金罪，判处其有期徒刑五年；被告人李鹏飞犯伪造国家机关公文、 印章罪，判处其有期徒刑二年，并处罚金人民币五万元，犯伪造公司印章罪，判处其有期徒刑一年，并 处罚金人民币三万元；被告人罗德顺犯挪用资金罪，判处其有期徒刑三年；责令被告人潘爱华向未名生 物医药有限公司返还人民币1275万元；扣押在案的伪造印章、公文由扣押机关依法予以 ...

Core Viewpoint - The article discusses the second-instance verdict of a legal case involving Unnamed Pharmaceutical (ST Unnamed, 002581.SZ), highlighting the reduced sentences for key individuals involved in financial misconduct and the implications for the company's governance and control [3][4]. Summary by Sections Legal Proceedings - The second-instance court sentenced Pan Aihua to five years for embezzlement and ordered him to return RMB 12.75 million to Unnamed Biopharmaceutical Co., Ltd. [3] - Li Pengfei received a two-year sentence for forgery and a one-year sentence for falsifying company seals, with fines totaling RMB 80,000 [3][4]. - Luo Deshun was sentenced to three years for embezzlement [3]. Background of the Case - The case traces back to August 2022 when the Shenzhen Stock Exchange issued a notice regarding investor complaints about a RMB 2.9 billion investment by Hangzhou Qiangxin Biotechnology Co., Ltd. in Unnamed's subsidiary, Xiamen Unnamed, which resulted in a 34% equity stake [4][5]. - Unnamed Pharmaceutical claimed that this transaction led to a significant loss of core assets and reported the matter to the police [5]. First Instance vs. Second Instance Verdict - The first-instance verdict imposed harsher penalties, including a total of 13 years for Pan Aihua and 8 years for Li Pengfei [6]. - The second-instance court found that the investment by Hangzhou Qiangxin was an abnormal capital increase but did not constitute embezzlement, as it did not result in actual financial loss to the company [7][8]. Court's Reasoning - The court noted that the actions of Pan Aihua and others were aimed at maintaining control over the company rather than illegally appropriating assets, indicating that their intent was defensive rather than criminal [9]. - The court emphasized that the capital increase did not lead to a loss of company assets or value, as the individuals involved did not benefit financially from the transaction [8][9].

"二审改判肯定了潘爱华等三人的主观目的并非非法占有公司财产，而是出于对公司控制权的维护…… 法院作出了有担当的判决。" 第一财经获悉，淄博市中级人民法院日前对未名医药（ST未名，002581.SZ）股权纠纷案作出二审判 决。 根据判决书，被告人潘爱华犯挪用资金罪，判处其有期徒刑五年；被告人李鹏飞犯伪造国家机关公文、 印章罪，判处其有期徒刑二年，并处罚金人民币五万元，犯伪造公司印章罪，判处其有期徒刑一年，并 处罚金人民币三万元；被告人罗德顺犯挪用资金罪，判处其有期徒刑三年；责令被告人潘爱华向未名生 物医药有限公司返还人民币1275万元；扣押在案的伪造印章、公文由扣押机关依法予以销毁。 潘爱华是未名医药创始人和前任董事长；罗德顺为未名生物医药有限公司（下称"厦门未名"）原董事长 兼总经理；李鹏飞是杭州强新生物科技有限公司（下称"杭州强新"）的法定代表人。 和一审判决相比，二审法院撤销了三人的职务侵占罪，对应的刑期和罚金都大幅减少。 与此同时，未名医药免去未名医药原董事长潘爱华在北京科兴的董事、董事长及法定代表人职务，免去 罗德顺在北京科兴的监事职务。潘爱华、罗德顺、杨晓敏三人于2022年11月被捕入狱。 厦门未名 ...

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.02% on December 26, with Jindike leading the drop, while the Shanghai Composite Index rose by 0.1% and the Shenzhen Component Index increased by 0.54% [1] Group 1: Market Performance - The closing prices and performance of key biopharmaceutical stocks showed mixed results, with Heyi Biotech rising by 3.17% to 71.61 and Jindike falling by 2.54% to 21.88 [1][2] - The trading volume for Heyi Biotech was 33,900 shares, with a transaction value of 239 million yuan, while Jindike had a trading volume of 38,900 shares and a transaction value of 85.44 million yuan [1][2] Group 2: Capital Flow - The biopharmaceutical sector saw a net outflow of 185 million yuan from institutional investors, while retail investors had a net inflow of 142 million yuan [2] - Key stocks like Gann Li Pharmaceutical had a net inflow of 13.59 million yuan from institutional investors, but a net outflow of 24.81 million yuan from retail investors [3]

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]

Core Viewpoint - The biopharmaceutical sector experienced a rise of 0.76% on December 17, with ST Weiming leading the gains. The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1]. Group 1: Stock Performance - ST Weiming (002581) closed at 7.49, with a gain of 5.05% and a trading volume of 58,400 shares, amounting to a transaction value of 43.46 million yuan [1]. - Wendi Pharmaceutical (688488) closed at 14.59, up 4.36%, with a trading volume of 56,400 shares and a transaction value of 80.52 million yuan [1]. - Kanghua Biological (300841) closed at 75.75, increasing by 2.98%, with a trading volume of 13,700 shares and a transaction value of 102 million yuan [1]. - Wan Ze Co., Ltd. (000534) closed at 23.31, up 2.24%, with a trading volume of 226,800 shares and a transaction value of 519 million yuan [1]. - Other notable stocks include Kang Le Wei Shi (920575) at 10.28 (+1.88%), Gan Li Pharmaceutical (603087) at 66.80 (+1.71%), and Anke Biological (300009) at 9.67 (+1.58%) [1]. Group 2: Capital Flow - The biopharmaceutical sector saw a net outflow of 344 million yuan from institutional investors, while retail investors experienced a net inflow of 441 million yuan [2]. - The capital flow for ST Weiming showed a net inflow of 14.06 million yuan from institutional investors, while retail investors had a net outflow of 645.75 million yuan [3]. - Kanghua Biological had a net inflow of 13.85 million yuan from institutional investors, with retail investors also experiencing a net outflow of 625.92 million yuan [3].

未名医药公告称，公司第六届董事会第十次会议审议通过《关于拟对控股孙公司新增财务资助的议 案》。因控股孙公司固康药业经营发展需求，公司拟以闲置自有资金向其提供不超4500万元财务资助， 年利率1.3%，借款期限自董事会审议通过之日起12个月内。董事会授权管理层签署相关协议。本次资 助不构成关联交易和重大资产重组，无需提交股东会审议。表决结果为11票同意、0票反对、0票弃权。 ...

每经AI快讯，ST未名（SZ 002581，收盘价：7.4元）12月5日晚间发布公告称，公司第六届第十次董事 会会议于2025年12月4日以通讯方式召开。会议审议了《关于拟对控股孙公司新增财务资助的议案》等 文件。 2025年1至6月份，ST未名的营业收入构成为：制药业务分部占比100.0%。 （记者 曾健辉） 截至发稿，ST未名市值为49亿元。 每经头条（nbdtoutiao）——秒光、售罄！银行大额存单成稀缺资源，2%以上产品很难抢，有的门槛高 达1000万元！专家：存款利率或长期下行 ...

关于拟对控股孙公司新增财务资助的公告 证券代码：002581 证券简称：ST未名 公告编号：2025-086 山东未名生物医药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、借款对象：山东未名生物医药股份有限公司（以下简称"公司"）控股 孙公司四川固康药业有限责任公司（以下简称"固康药业"） 2、借款金额：不超过 4,500 万元人民币。 3、借款期限：自董事会审议通过之日起 12 个月之内。 4、借款利率：借款年利率为 1.3%。 5、履行的审议程序：2025 年 12 月 4 日，公司召开第六届董事会第十次会 议审议通过了《关于拟对控股孙公司新增财务资助的议案》，同意公司向控股孙 公司固康药业新增财务资助事宜。 6、固康药业的其他股东未就本次财务资助事项提供同比例财务资助及担保， 公司作为固康药业的控股股东，能够对固康药业实施有效的业务、资金管理和风 险控制，确保公司资金安全。本次财务资助事项整体风险可控，不存在损害公司 及股东、特别是中小股东利益的情形。 公司于 2025 年 12 月 4 日召开第六届董事会第十次会议 ...

证券代码：002581 证券简称：ST未名 公告编号：2025-087 山东未名生物医药股份有限公司 第六届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司(以下简称"公司")第六届董事会第十次会 议于 2025 年 12 月 4 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实际 参加表决董事 11 人，分别为：岳家霖、刘文俊、徐隽雄、周婷、陈星、史晓如、 黄桂源、蔡艳红、张荣富、杨军、夏阳。董事会会议通知已于 2025 年 12 月 2 日 以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集和召开 符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。本次会议 审议了如下议案： 1、山东未名生物医药股份有限公司第六届董事会第十次会议决议。 特此公告。 山东未名生物医药股份有限公司 （一）审议通过了《关于拟对控股孙公司新增财务资助的议案》 根据公司控股孙公司四川固康药业有限责任公司（以下简称"固康药业"） 的经营发展需求，在保障公司后续建设、运营 ...